SCHEMBL296164

SCHEMBL296164

CC(CCN1CCC(NS(C)(=O)=O)CC1)(C(=O)NCc1ccc(C#N)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.42
CCR5 P51681 3/20 0.41
TACR3 P29371 4/20 0.40
TACR2 P21452 3/20 0.40
TACR1 P25103 3/20 0.40
KCNH2 Q12809 2/20 0.39
CACNA1I Q9P0X4 1/20 0.39
THRB P10828 1/20 0.38
HRH1 P35367 1/20 0.38
CCR3 P51677 1/20 0.38
EPHX2 P34913 1/20 0.38
MAOA P21397 1/20 0.38
ACHE P22303 1/20 0.38
MAOB P27338 1/20 0.38
MCHR1 Q99705 1/20 0.37
CCR2 P41597 1/20 0.37
P2RX7 Q99572 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12942932 0.94 PDE5A (0.41) PDE5ACCR5TACR3KCNH2THRB
SCHEMBL296022 0.91 TACR3 (0.43) TACR3TACR2TACR1KCNH2CACNA1I
SCHEMBL8034347 0.90 TACR3 (0.42) TACR3TACR2TACR1KCNH2CACNA1I
SCHEMBL296032 0.90 TACR3 (0.46) TACR3TACR2TACR1KCNH2CACNA1I
SCHEMBL297584 0.88 TACR3 (0.43) CCR5TACR3TACR2TACR1KCNH2
SCHEMBL298428 0.87 TACR3 (0.45) CCR5TACR3TACR2TACR1KCNH2
SCHEMBL3862403 0.87 CCR5 (0.45) CCR5TACR3TACR2TACR1EPHX2
SCHEMBL298155 0.86 DDR1 (0.43) TACR3TACR2TACR1KCNH2CACNA1I
SCHEMBL297799 0.86 TACR3 (0.49) TACR3TACR2TACR1KCNH2CACNA1I
SCHEMBL299660 0.85 TACR3 (0.44) TACR3TACR2TACR1KCNH2CACNA1I

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200982-B1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-03-14 EP disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 US disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 PDE5A 912/4885CCR5 1096/4885TACR3 95/4885
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 PDE5A 912/4885CCR5 1096/4885TACR3 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.